Related Experiment Video
Updated: Mar 19, 2026
07:25
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
18.3K
Biosimilars: Still Not Quite Ready for Prime Time
P & T : a Peer-Reviewed Journal for Formulary Management
|June 18, 2016
Summary
Biosimilars offer significant cost savings for healthcare payers and patients. However, their future acceptance and prescription rates remain uncertain.
Area of Science:
- Pharmacoeconomics
- Drug development
- Healthcare policy
Background:
- Biosimilars are biological products highly similar to approved reference medicines.
- They offer a pathway to reduce healthcare costs and increase patient access to biologic therapies.
- Uncertainty exists regarding the clinical adoption and prescribing patterns of these novel agents.
Purpose of the Study:
- To analyze the potential economic impact of biosimilars.
- To explore factors influencing the acceptance and prescription of biosimilars.
- To forecast the market integration of biosimilar agents.
Main Methods:
- Literature review of current biosimilar market data.
- Analysis of payer and physician surveys on adoption barriers.
- Economic modeling of potential cost savings.
Main Results:
- Biosimilars present a substantial opportunity for cost reduction in healthcare.
- Key barriers to widespread adoption include prescriber education and formulary placement.
- Predicting the precise timeline for market penetration is challenging.
Conclusions:
- Biosimilars hold significant promise for economic benefits in healthcare systems.
- Addressing prescriber confidence and ensuring favorable market access are crucial for uptake.
- Further research is needed to fully understand and optimize biosimilar integration.
Related Concept Videos
01:28Drug Products: Biologics, Biosimilars and Interchangeables
345
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
345
01:16Bioequivalence: Overview
2.2K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
2.2K
01:26Pharmaceutical Equivalents
250
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
250
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
205
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
205
01:13Bioequivalence studies: Biowaivers
376
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
376
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
236
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
236